Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tempest Therapeutics, Inc. Director's Dealing 2021

Feb 9, 2021

34632_dirs_2021-02-09_0ede8f14-df26-42af-a5d2-e53601bad750.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Millendo Therapeutics, Inc. (MLND)
CIK: 0001544227
Period of Report: 2021-02-01

Reporting Person: Minai-Azary Jennifer Lynn (Chief Financial Officer)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $1.08 2023-08-21 Common Stock (2969.0) Direct
Stock Option (right to buy) $2.69 2024-05-27 Common Stock (989.0) Direct
Stock Option (right to buy) $4.44 2026-01-27 Common Stock (12382.0) Direct
Stock Option (right to buy) $8.47 2026-11-02 Common Stock (12840.0) Direct
Stock Option (right to buy) $16.4 2028-08-23 Common Stock (11160.0) Direct
Stock Option (right to buy) $10.48 2029-01-31 Common Stock (18000.0) Direct
Stock Option (right to buy) $11.59 2029-06-20 Common Stock (7000.0) Direct
Stock Option (right to buy) $7.94 2030-01-30 Common Stock (20000.0) Direct
Stock Option (right to buy) $2.0 2030-05-24 Common Stock (20000.0) Direct

Footnotes

F1: Shares subject to this option are fully vested.

F2: Twenty-five percent (25%) of the shares subject to this option vested on August 20, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

F3: Twenty-five percent (25%) of the shares subject to this option vested on January 31, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

F4: Twenty-five percent (25%) of the shares subject to this option vested on June 20, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

F5: Twenty-five percent (25%) of the shares subject to this option vested on January 31, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

F6: Fifty percent (50%) of the shares subject to this option vested on December 31, 2020, and one twelfth (1/12th) of the remaining shares subject to this option shall vest in equal monthly installments thereafter, subject to the Reporting Person continuing to provide service to the Issuer through each such date.